It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Abbreviations ADCs Adenocarcinomas ALDH1A1 Aldehyde dehydrogenase 1 family member A1 ALK Anaplastic lymphoma kinase CSC Cancer stem cell CCL20 Chemokine (C-C motif) ligand 20 CCR6 chemokine receptor 6 DGE Differential gene expression DTP Drug-tolerant persister EGFR Epidermal growth factor receptor EML4 Echinoderm microtubule-associated protein-like 4 ELISA Enzyme-linked immunosorbent assay FOS Fos Proto-Oncogene NANOG Homeobox protein NANOG ICAM-1 Intercellular adhesion molecule 1 IL-17 Interleukin-17 LCOs Lung cancer organoids MUC5AC Mucin-5AC NSCLC Non-small cell lung carcinoma POU5F1 POU Class 5 Homeobox 1 PROM1 Prominin 1 PTGS2 Prostaglandin-endoperoxide synthase 2 RORɣ Retinoid-related orphan receptor-γ S100A9 S100 calcium-binding protein A9 scRNA-seq Single-cell RNA sequencing TCGA-LUAD The Cancer Genome Atlas Lung Adenocarcinoma Th17 T helper-17 lymphocytes TKIs Tyrosine kinase inhibitors TNF Tumor necrosis factor UMI Unique molecular index UMAP Uniform Manifold Approximation and Projection Dear Editor, Non-small cell lung carcinoma (NSCLC) accounts for more than 85% of all lung cancers [ 1]. Differential gene expression (DGE) analysis of drug-resistant and drug-sensitive TS485T-O LCOs revealed that the interleukin-17 (IL-17) signaling pathway was enriched in both crizotinib-resistant and alectinib-resistant tumor organoids ( Supplementary Figure S2C-D). [...]we found that the actin cytoskeleton regulatory pathway was downregulated in both FA34-O crizotinib-resistant and alectinib-resistant tumor organoids ( Supplementary Figure S2E-F). Abbreviations: Anterior gradient 2 (AGR2); Chemokine (C-C motif) ligand 20 (CCL20); BPI fold containing family A, member 1 (BPIFA1); Cancer susceptibility candidate 1 (CASC1); Cell division cycle 20B (CDC20B); Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6); Cilia and flagella associated protein 126 (CFAP126); Coiled-Coil Domain Containing 170 (CCDC170); Coronin 2A (CORO2A); C-X-C motif chemokine ligand 8 (CXCL8); Dynein axonemal assembly factor 1 (DNAAF1); Dynein axonemal heavy chain 7 (DNAH7); EF-hand domain family member B (EFHB); Ferritin heavy chain 1 (FTH1); GINS complex subunit (GINS1); Hypoxia-inducible factors (HIF); Leucine Rich Repeat Containing 46 (LRRC46); Matrix metallopeptidase 1 (MMP1); Meiosis specific nuclear structural 1 (MNS1); Nicotinamide phosphoribosyltransferase (NAMPT); Nucleotide oligomerization domain (NOD); Myocardial infarction associated transcript (MIAT); Paternally Expressed 10 (PEG10); PIH1 domain containing 3 (PIH1D3); Primary cilia formation (PIFO); Prosaposin (PSAP); Ras-proximate-1 (RAP1); Radial spoke head component 1 (RSPH1); Regulator of cell cycle (RGCC); Rho family GTPase 1 (RND1); Rhophilin associated tail protein 1 like (ROPN1L); Ribosomal Protein L10 (RPL10); Insulin like growth factor binding protein 5 (IGFBP5); Intercellular adhesion molecule 1 (ICAM-1); Interleukin-17 (IL-17); S100 Calcium Binding Protein A9 (S100A9); Trefoil factor 1 (TFF-1); Tetraspanin 1 (TSPAN1); Threonine tyrosine kinase (TTK); T helper-17 lymphocytes (Th17); WAP four-disulfide core domain protein 2 (WFDC2) CCL20, mainly produced by mucosal lymphoid tissues, is a chemokine that directs lymphocyte migration toward epithelial cells.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Department of Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong SAR, P. R. China
2 Nancy B. and Jake L. Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, USA
3 Cardiothoracic Surgical Department, Queen Mary Hospital, Hong Kong SAR, P. R. China
4 School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, P. R. China
5 Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA